Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

被引:10
作者
Burke, G. A. Amos [1 ]
Beishuizen, Auke [2 ]
Bhojwani, Deepa [3 ]
Burkhardt, Birgit [4 ]
Minard-Colin, Veronique [5 ]
Norris, Robin E. [6 ]
Kabickova, Edita [7 ,8 ]
Pinarli, F. Guclu [9 ]
Tacyildiz, Nurdan [10 ]
Howes, Angela [11 ]
de Jong, Jan [12 ]
Liu, Grace [13 ]
Nottage, Kerri [13 ]
Salman, Mariya [13 ]
de Trixhe, Xavier Woot [14 ]
Cairo, Mitchell [15 ]
机构
[1] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Dept Paediat Haematol Oncol & Palliat Care, Cambridge, England
[2] Princess Maxima Ctr Pediat Oncol, Dept Hematol & Oncol, Utrecht, Netherlands
[3] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90007 USA
[4] Univ Hosp Munster, Pediat Hematol & Oncol, Munster, Germany
[5] Gustave Roussy, Dept Child & Adolescent Canc, Paris, France
[6] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[7] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic
[8] Univ Hosp Motol, Prague, Czech Republic
[9] Gazi Univ, Dept Pediat Oncol, Ankara, Turkey
[10] Ankara Univ, Dept Pediat Hematol & Oncol, Ankara, Turkey
[11] Janssen R&D LLC, Clin Oncol, High Wycombe, Bucks, England
[12] Janssen R&D LLC, Clin Pharmacol, San Diego, CA USA
[13] Janssen R&D LLC, Clin Oncol, Raritan, NJ USA
[14] Janssen R&D LLC, Pharmacometr, Beerse, Belgium
[15] New York Med Coll, Dept Pediat Med Pathol Microbiol & Immunol & Cell, Valhalla, NY 10595 USA
关键词
KINASE INHIBITOR IBRUTINIB; CELL;
D O I
10.1038/s41375-020-0749-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:2271 / 2275
页数:5
相关论文
共 13 条
[1]   Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].
Advani, Ranjana H. ;
Buggy, Joseph J. ;
Sharman, Jeff P. ;
Smith, Sonali M. ;
Boyd, Thomas E. ;
Grant, Barbara ;
Kolibaba, Kathryn S. ;
Furman, Richard R. ;
Rodriguez, Sara ;
Chang, Betty Y. ;
Sukbuntherng, Juthamas ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Hedrick, Eric ;
Fowler, Nathan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94
[2]   Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group [J].
Cairo, Mitchell ;
Auperin, Anne ;
Perkins, Sherrie L. ;
Pinkerton, Ross ;
Harrison, Lauren ;
Goldman, Stanton ;
Patte, Catherine .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (06) :859-869
[3]   Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model [J].
Chu, Yaya ;
Lee, Sanghoon ;
Shah, Tishi ;
Yin, Changhong ;
Barth, Matthew ;
Miles, Rodney R. ;
Ayello, Janet ;
Morris, Erin ;
Harrison, Lauren ;
Van de Ven, Carmella ;
Galardy, Paul ;
Goldman, Stanton C. ;
Lim, Megan S. ;
Hermiston, Michelle ;
McAllister-Lucas, Linda M. ;
Giulino-Roth, Lisa ;
Perkins, Sherrie L. ;
Cairo, Mitchell S. .
ONCOIMMUNOLOGY, 2019, 8 (01)
[4]   Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma [J].
Davis, R. Eric ;
Ngo, Vu N. ;
Lenz, Georg ;
Tolar, Pavel ;
Young, Ryan M. ;
Romesser, Paul B. ;
Kohlhammer, Holger ;
Lamy, Laurence ;
Zhao, Hong ;
Yang, Yandan ;
Xu, Weihong ;
Shaffer, Arthur L. ;
Wright, George ;
Xiao, Wenming ;
Powell, John ;
Jiang, Jian-Kang ;
Thomas, Craig J. ;
Rosenwald, Andreas ;
Ott, German ;
Muller-Hermelink, Hans Konrad ;
Gascoyne, Randy D. ;
Connors, Joseph M. ;
Johnson, Nathalie A. ;
Rimsza, Lisa M. ;
Campo, Elias ;
Jaffe, Elaine S. ;
Wilson, Wyndham H. ;
Delabie, Jan ;
Smeland, Erlend B. ;
Fisher, Richard I. ;
Braziel, Rita M. ;
Tubbs, Raymond R. ;
Cook, J. R. ;
Weisenburger, Dennis D. ;
Chan, Wing C. ;
Pierce, Susan K. ;
Staudt, Louis M. .
NATURE, 2010, 463 (7277) :88-U97
[5]   Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling [J].
de Zwart, L. ;
Snoeys, J. ;
De Jong, J. ;
Sukbuntherng, J. ;
Mannaert, E. ;
Monshouwer, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) :548-557
[6]   Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies [J].
Egan, Grace ;
Goldman, Stan ;
Alexander, Sarah .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (06) :1071-1085
[7]   Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies [J].
Gayko, Urte ;
Fung, Mann ;
Clow, Fong ;
Sun, Steven ;
Faust, Elizabeth ;
Price, Samiyeh ;
James, Danelle ;
Doyle, Margaret ;
Bari, Samina ;
Zhuang, Sen Hong .
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 :82-94
[8]   A Study of Rituximab and Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children with Recurrent/Refractory B-Cell (CD20+) Non-Hodgkin Lymphoma and Mature B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group [J].
Griffin, Timothy C. ;
Weitzman, Sheila ;
Weinstein, Howard ;
Chang, Myron ;
Cairo, Mitchell ;
Hutchison, Robert ;
Shiramizu, Bruce ;
Wiley, Joseph ;
Woods, Deborah ;
Barnich, Margaret ;
Gross, Thomas G. .
PEDIATRIC BLOOD & CANCER, 2009, 52 (02) :177-181
[9]  
IMBRUVICA (ibrutinib), 2018, IMBRUVICA IBR
[10]   Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588 [J].
Sauter, Craig S. ;
Verwys, Stephanie L. ;
McCall, Susan J. ;
Miller, Shoshana T. ;
Courtien, Amanda I. ;
Schoder, Heiko ;
Harris, Pamela ;
Matasar, Matthew J. ;
Younes, Anas ;
Moskowitz, Craig H. .
BLOOD, 2016, 128 (22)